Full metadata record

DC Field Value Language
dc.contributor.authorLee, So Jin-
dc.contributor.authorYhee, Ji Young-
dc.contributor.authorKim, Sun Hwa-
dc.contributor.authorKwon, Ick Chan-
dc.contributor.authorKim, Kwangmeyung-
dc.date.accessioned2024-01-20T11:02:52Z-
dc.date.available2024-01-20T11:02:52Z-
dc.date.created2021-09-05-
dc.date.issued2013-11-28-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/127423-
dc.description.abstractStructural modifications of the siRNA backbone improved its physiochemical properties for incorporating in gene carriers without loss of gene-silencing efficacy. These modifications provide a wider variety of choice of vector systems for siRNA delivery. We developed a tumor-targeted siRNA delivery system using polymerized siRNA (poly-siRNA) and natural polymer gelatin. The polymerized siRNA (poly-siRNA) was prepared through self-polymerization of thiol groups at the 5'-end of sense and anti-sense strands of siRNA and was encapsulated in the self-assembled thiolated gelatin (tGel) nanoparticles (NPs) with chemical cross-linking. The resulting poly-siRNA-tGel (psi-tGel) nanoparticles (average of 145 nm in diameter) protect siRNA molecules from enzymatic degradation, and can be reversibly reduced to release functional siRNA molecules in reductive conditions. The psi-tGel NPs presented efficient siRNA delivery in red fluorescence protein expressing melanoma cells (RFP/B16F10) to down-regulate target gene expression. In addition, the NPs showed low toxicity at a high transfection dose of 125 mu g/ml psi-tGel NPs, which included 1 mu M of siRNA molecules. In tumor-bearing mice, the psi-tGel NPs showed 2.8 times higher tumor accumulation than the naked poly-siRNA, suggesting tumor-targeted siRNA delivery of psi-tGel NPs. Importantly, the psi-tGel NPs induced effective tumor RFP gene silencing in vivo without remarkable toxicity. The psi-tGel NPs have great potential for a systemic siRNA delivery system for cancer therapy, based on their characteristics of low toxicity, tumor accumulation, and effective siRNA delivery. (C) 2013 Elsevier B. V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.subjectDRUG-DELIVERY-
dc.subjectGENE DELIVERY-
dc.subjectCATIONIC LIPIDS-
dc.subjectGLUTATHIONE-
dc.subjectTOXICITY-
dc.subjectTHERAPEUTICS-
dc.subjectSTABILITY-
dc.subjectCOMPLEXES-
dc.subjectEFFICACY-
dc.subjectTHERAPY-
dc.titleBiocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2013.09.002-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, v.172, no.1, pp.358 - 366-
dc.citation.titleJOURNAL OF CONTROLLED RELEASE-
dc.citation.volume172-
dc.citation.number1-
dc.citation.startPage358-
dc.citation.endPage366-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000327601200040-
dc.identifier.scopusid2-s2.0-84884641829-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusDRUG-DELIVERY-
dc.subject.keywordPlusGENE DELIVERY-
dc.subject.keywordPlusCATIONIC LIPIDS-
dc.subject.keywordPlusGLUTATHIONE-
dc.subject.keywordPlusTOXICITY-
dc.subject.keywordPlusTHERAPEUTICS-
dc.subject.keywordPlusSTABILITY-
dc.subject.keywordPlusCOMPLEXES-
dc.subject.keywordPlusEFFICACY-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordAuthorGelatin-
dc.subject.keywordAuthorNanoparticles-
dc.subject.keywordAuthorPolymerized siRNA-
dc.subject.keywordAuthorsiRNA delivery system-
dc.subject.keywordAuthorTumor-targeted delivery-
Appears in Collections:
KIST Article > 2013
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE